Pharma giant withdraws challenge to generic HIV anti-retroviral drug

Gilead has dropped its appeal against the High Court’s refusal to grant an injunction against generic manufacturers.

Published

21 December 2017

From

Irish Times

This Company Is About to Flood the US With Cheap HIV Drugs

U.S. patents on key components for some important HIV therapies are poised to expire starting in December and Laurus Labs Ltd. -- the Hyderabad, India-based company which owns the facility -- is gearing up to cash in.

Published

04 December 2017

From

Bloomberg

Gilead loss of generic HIV drug battle a boost for gay community

Published

09 November 2017

From

The Irish Times

Gilead Continues To Block Ireland From Sourcing Generic Truvada

Gilead Sciences, the company that supplies Ireland with the drug Truvada, will have a full court hearing in mid-October to determine whether the Irish Health and Safety Executive (HSE) can source a generic analogue of the drug from the pharmaceutical giant’s competitors. In July, GCN reported that Gilead was taking legal action to stop the HSE from securing generic drug from Actavis and Mylan, the company’s competitors, for the purposes of HIV prevention as PrEP.

Published

16 October 2017

From

Gay Community News

Brand Name Vs Generic Drugs: The Fight Continues

Many patients and practitioners are looking to generics to ease the pressure of skyrocketing antiretroviral (ART) drug prices, but according to Rochelle P Walensky, MD, Professor of Medicine at Harvard Medical School, they shouldn’t hold their breath.

Published

10 October 2017

From

MD Mag

New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year.

Published

22 September 2017

From

UNAIDS

Generic PrEP in France and Scotland challenges access across the UK

The issue of drug procurement and pricing is complex but it is difficult to see how different patents should apply within Europe, and especially not within the UK.

Published

08 September 2017

From

HIV i-Base

Did HIV Pharma “Pay to Delay” Generic Truvada?

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

Published

04 September 2017

From

Poz